Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell Therapy
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell Therapy
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Featuring an interview with Dr Beth Faiman, including the following topics:
- Clinical practice background and historical view of treatment for multiple myeloma (MM) (0:00)
- Fundamental principles associated with chimeric antigen receptor (CAR) T-cell therapy (7:19)
- Sequencing of CAR T-cell therapy and bispecific antibodies in the MM treatment landscape (9:00)
- Patient eligibility to receive CAR T-cell therapy (13:23)
- Differentiating among approved CAR T-cell therapies for MM (18:18)
- Durability of responses to CAR T-cell therapy for MM (24:01)
- Neurotoxicity with CAR T-cell therapies for MM (26:26)
- Minimal residual disease monitoring in MM (29:39)
- Support systems for the management of toxicities associated with CAR T-cell therapy (35:10)
- Patients with MM experiencing durable responses to CAR T-cell therapy (43:11)
NCPD information and select publications
Pas encore de commentaire